None listed
Conditions
Brief summary
The underlying hypothesis for CACHE is that patients with congestive heart failure who receive clopidogrel will experience fewer heart failure outcomes when compared to patients receiving aspirin.
Interventions
Clopidogrel 75mg oral tablet taken once per day for an average of 3 years (maximum 5 years).
Sponsors
University of Sydney
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men or women age >18 years 2. Symptomatic heart failure 3. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) of >600pg/mL OR NT-proBNP >400pg/mLa + Heart Failure (HF) hospitalisation within last 12 months 4. Treatment with an angiotensin converting enzyme (ACE) inhibitor (unless not tolerated) and ongoing treatment with a diuretic 5. Provision of written informed consent
Exclusion criteria
1. Contraindication to aspirin or clopidogrel 2. Indication for chronic anti-coagulation 3. Heart failure due to a reversible cause or hypertrophic or infiltrative cardiomyopathy 4. Unstable heart failure or treatment regimen 5. Life-limiting systemic illness 6. Severe chronic obstructive pulmonary disease (COPD) (as evidenced by history of mechanical ventilation, need for home oxygen, or treatment with oral corticosteroids) for more than 3 continuous days within 12 months 7. Conditions that might interfere with protocol compliance
Outcome results
None listed